|
|
WelcomeWorld Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.
Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free service delivered by FeedBurner).
Non progredi est regredi. |
||||
Pharmaceutical Companies[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]Sponsored Ads Pharmaceutical RSS NewsStart your day with worldwide pharmaceutical news[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]  European Commission - Pharmaceuticals US Food and Drug Administration
World Pharma News .net / Published NewsOur RSS News Channels    
Sponsored Ads |
Financial News Channel
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. 
Roche is investing 215 million Swiss francs (136 million euros) in research, development and production at its site in Penzberg, near Munich. The money will be used to construct a multi-purpose building for Roche Diagnostics. 
Bayer HealthCare AG acquires the German biotech company DIREVO Biotech AG, Cologne. With the acquisition of the biotech company specialized in protein engineering, Bayer strengthens the research competence in biologicals of its pharmaceutical division Bayer Schering Pharma. 
In the first six months of 2008, Nycomed’s adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effects of last year’s restructuring and as a result of the successful integration. 
Net sales for the second quarter of 2008 increased 18 percent to $2,823 million, compared to $2,386 million in the second quarter of 2007. Net income for the second quarter of 2008 totaled $539 million, compared to $515 million for the same period of 2007 (up 5 percent), while diluted earnings per share increased to $0.65 from $0.63 (up 3 percent). 
The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 (+9.0%). On account of the strength of the euro against the US dollar and the Japanese yen, growth after consolidation in euro was +2.1% with net sales of EUR 5,522 million compared with EUR 5,407 million in the first six months of 2007. 